Preclinical assessment is constantly evolving, shaped by technological advances, new scientific discoveries and evolving societal needs. In this article, I will share some predictions about the future of preclinical assessment.
Increasing personalization
One of the most important trends in medicine is the growing demand for personalized medicine, which tailors treatment to individual patient characteristics. We can expect this trend to affect preclinical evaluation as well. Thanks to advances in genetics and bioinformatics, we can expect increasing use of technologies such as gene sequencing and bioinformatics to more accurately model and predict the body's response to new drugs.
Improved in vitro technology
In vitro technology will continue to evolve, allowing more accurate and sophisticated cell and tissue models for drug testing. The development of organoid and organ chip technology - microscopic models of organs on chips - will allow more accurate modeling of the effects of drugs on specific organs and on interactions between different organs.
Use of artificial intelligence
Artificial intelligence (AI) is likely to play an increasingly important role in preclinical evaluation. AI can help speed up the drug discovery process, predict side effects, analyze large data sets and much more. We can expect the use of AI in preclinical evaluation to grow with advances in machine learning algorithms and the availability of large biomedical data sets.
Reducing the use of animals
Recent years have brought a growing tension to reduce and replace the use of animals in research. New technologies such as organoids, organ chips and better in silico models can help reduce - and in some cases even replace - the use of animals in preclinical evaluation.
Summary
The future of preclinical evaluation looks promising. We can expect that new technologies and approaches, such as better personalization, improved in vitro technology, artificial intelligence and reduced animal use, will contribute to the development of more effective, safe and patient-directed drugs and therapies. In the dynamic world of preclinical evaluation, one thing is certain - we will see continued innovation and progress.
